Overall rank by patents
#6,799
Across all tracked assignees
USPTO PatentsView assignee record - 49 granted patents across 6 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
The verdict
Intercept holds 49 US patents across 6 technology areas, rank #6,799 of 50,000 tracked assignees.
Intercept Pharmaceuticals, Inc. has been granted 49 US utility patents between 2015 and 2025, placing Intercept Pharmaceuticals, Inc. at rank #6,799 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.8 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Intercept Pharmaceuticals, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Intercept sits between Imertech SAS (49 patents, rank #6,795) and Jasco Products Company Llc (49 patents, rank #6,803) - the closest US assignees by grant volume. The composite Innovation Score of 32.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 26 grants, compared with 23 in the 2015–2019 window, a +13% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Intercept Pharmaceuticals, Inc.'s 13.8 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Intercept Pharmaceuticals, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Imertech SAS
49 patents
Insmed Incorporated
49 patents
Institute for Musculoskeletal Science and Education, Ltd.
49 patents
Interactions LLC
49 patents
Inventus Power, Inc.
49 patents
JAPAN AGENCY FOR MARINE-EARTH SCIENCE AND TECHNOLOGY
49 patents
JIANGSU UNIVERSITY OF SCIENCE AND TECHNOLOGY
49 patents
Jasco Products Company LLC
49 patents
Intercept Pharmaceuticals, Inc.
49 patents
What this shows Intercept holds 49 patents at rank #6,799, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #6,799 in granted patent volume.
Other assignees with the most granted patents in Intercept's primary technology class.
Intercept's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
32 Top 59% higher than 41% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 3 | 6.1% |
| 2016 | 3 | 6.1% |
| 2017 | 7 | 14.3% |
| 2018 | 4 | 8.2% |
| 2019 | 6 | 12.2% |
| 2020 | 11 | 22.4% |
| 2021 | 6 | 12.2% |
| 2022 | 6 | 12.2% |
| 2023 | 1 | 2.0% |
| 2025 | 2 | 4.1% |
Top 6 of 6 technology areas
Overall rank by patents
#6,799
Across all tracked assignees
32.5 out of 100
How to use this portfolio
Intercept's 49 grants land it in the top 59% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.